Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model.
Identifieur interne : 000174 ( PubMed/Corpus ); précédent : 000173; suivant : 000175Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model.
Auteurs : Hua-Hao Fan ; Li-Qin Wang ; Wen-Li Liu ; Xiao-Ping An ; Zhen-Dong Liu ; Xiao-Qi He ; Li-Hua Song ; Yi-Gang TongSource :
- Chinese medical journal [ 2542-5641 ] ; 2020.
Abstract
Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed. However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those without such facilities or 2019-novel coronavirus (2019-nCoV). This study aims to repurpose the clinically approved drugs for the treatment of coronavirus disease 2019 (COVID-19) in a 2019-nCoV related coronavirus model.
DOI: 10.1097/CM9.0000000000000797
PubMed: 32149769
Links to Exploration step
pubmed:32149769Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model.</title><author><name sortKey="Fan, Hua Hao" sort="Fan, Hua Hao" uniqKey="Fan H" first="Hua-Hao" last="Fan">Hua-Hao Fan</name><affiliation><nlm:affiliation>Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Li Qin" sort="Wang, Li Qin" uniqKey="Wang L" first="Li-Qin" last="Wang">Li-Qin Wang</name></author><author><name sortKey="Liu, Wen Li" sort="Liu, Wen Li" uniqKey="Liu W" first="Wen-Li" last="Liu">Wen-Li Liu</name></author><author><name sortKey="An, Xiao Ping" sort="An, Xiao Ping" uniqKey="An X" first="Xiao-Ping" last="An">Xiao-Ping An</name></author><author><name sortKey="Liu, Zhen Dong" sort="Liu, Zhen Dong" uniqKey="Liu Z" first="Zhen-Dong" last="Liu">Zhen-Dong Liu</name></author><author><name sortKey="He, Xiao Qi" sort="He, Xiao Qi" uniqKey="He X" first="Xiao-Qi" last="He">Xiao-Qi He</name></author><author><name sortKey="Song, Li Hua" sort="Song, Li Hua" uniqKey="Song L" first="Li-Hua" last="Song">Li-Hua Song</name></author><author><name sortKey="Tong, Yi Gang" sort="Tong, Yi Gang" uniqKey="Tong Y" first="Yi-Gang" last="Tong">Yi-Gang Tong</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32149769</idno><idno type="pmid">32149769</idno><idno type="doi">10.1097/CM9.0000000000000797</idno><idno type="wicri:Area/PubMed/Corpus">000174</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000174</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model.</title><author><name sortKey="Fan, Hua Hao" sort="Fan, Hua Hao" uniqKey="Fan H" first="Hua-Hao" last="Fan">Hua-Hao Fan</name><affiliation><nlm:affiliation>Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Li Qin" sort="Wang, Li Qin" uniqKey="Wang L" first="Li-Qin" last="Wang">Li-Qin Wang</name></author><author><name sortKey="Liu, Wen Li" sort="Liu, Wen Li" uniqKey="Liu W" first="Wen-Li" last="Liu">Wen-Li Liu</name></author><author><name sortKey="An, Xiao Ping" sort="An, Xiao Ping" uniqKey="An X" first="Xiao-Ping" last="An">Xiao-Ping An</name></author><author><name sortKey="Liu, Zhen Dong" sort="Liu, Zhen Dong" uniqKey="Liu Z" first="Zhen-Dong" last="Liu">Zhen-Dong Liu</name></author><author><name sortKey="He, Xiao Qi" sort="He, Xiao Qi" uniqKey="He X" first="Xiao-Qi" last="He">Xiao-Qi He</name></author><author><name sortKey="Song, Li Hua" sort="Song, Li Hua" uniqKey="Song L" first="Li-Hua" last="Song">Li-Hua Song</name></author><author><name sortKey="Tong, Yi Gang" sort="Tong, Yi Gang" uniqKey="Tong Y" first="Yi-Gang" last="Tong">Yi-Gang Tong</name></author></analytic><series><title level="j">Chinese medical journal</title><idno type="eISSN">2542-5641</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed. However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those without such facilities or 2019-novel coronavirus (2019-nCoV). This study aims to repurpose the clinically approved drugs for the treatment of coronavirus disease 2019 (COVID-19) in a 2019-nCoV related coronavirus model.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32149769</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2542-5641</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Mar</Month><Day>06</Day></PubDate></JournalIssue><Title>Chinese medical journal</Title><ISOAbbreviation>Chin. Med. J.</ISOAbbreviation></Journal><ArticleTitle>Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/CM9.0000000000000797</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed. However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those without such facilities or 2019-novel coronavirus (2019-nCoV). This study aims to repurpose the clinically approved drugs for the treatment of coronavirus disease 2019 (COVID-19) in a 2019-nCoV related coronavirus model.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 2019-nCoV related pangolin coronavirus GX_P2V/pangolin/2017/ Guangxi was described. Whether GX_P2X uses angiotensin-converting enzyme 2 (ACE2) as the cell receptor was investigated by using small interfering RNA (siRNA) -mediated silencing of ACE2. The pangolin coronavirus model was used to identify drug candidates for treating 2019-nCoV infection. Two libraries of 2406 clinically approved drugs were screened for their ability to inhibit cytopathic effects on Vero E6 cells by GX_P2X infection. The antiviral activities and antiviral mechanisms of potential drugs were further investigated. Viral yields of RNAs and infectious particles were quantified by quantitative real-time polymerase chain reaction (qRT-PCR) and plaque assay, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The spike protein of coronavirus GX_P2V shares 92.2% amino acid identity with that of 2019-nCoV isolate Wuhan-hu-1, and uses ACE2 as the receptor for infection just like 2019-nCoV. Three drugs-cepharanthine (CEP), selamectin and mefloquine hydrochloride exhibited complete inhibition of cytopathic effects in cell culture at 10 μmol/L. CEP demonstrated the most potent inhibition of GX_P2V infection, with a concentration for 50% of maximal effect [EC50] of 0.98 μmol/L. The viral RNA yield in cells treated with 10 μmol/L CEP was 15,393-fold lower than in cells without CEP treatment ([6.48 ± 0.02] × 10vs. 1.00 ± 0.12, t = 150.38, P < 0.001) at 72 h post-infection (p.i.). Plaque assays found no production of live viruses in media containing 10 μmol/L CEP at 48 h p.i. Furthermore, we found CEP has potent antiviral activities against both viral entry (1.00 ± 0.37 vs. 0.46 ± 0.12, t = 2.42, P < 0.05) and viral replication (1.00 ± 0.43 vs. [6.18 ± 0.95] × 10, t = 3.98, P < 0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our pangolin coronavirus GX_P2V is a workable model for 2019-nCoV research. CEP, selamectin and mefloquine hydrochloride are potential drugs for treating 2019-nCoV infection. Our results strongly suggest that CEP is a wide-spectrum inhibitor of pan-betacoronavirus, and clinical trial of CEP for treatment of 2019-nCoV infection is warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Hua-Hao</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-Qin</ForeName><Initials>LQ</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wen-Li</ForeName><Initials>WL</Initials></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Xiao-Ping</ForeName><Initials>XP</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhen-Dong</ForeName><Initials>ZD</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xiao-Qi</ForeName><Initials>XQ</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Li-Hua</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Yi-Gang</ForeName><Initials>YG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin Med J (Engl)</MedlineTA><NlmUniqueID>7513795</NlmUniqueID><ISSNLinking>0366-6999</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32149769</ArticleId><ArticleId IdType="doi">10.1097/CM9.0000000000000797</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000174 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000174 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:32149769
|texte= Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32149769" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidV1
| This area was generated with Dilib version V0.6.33. |  |